Research ExplorerPublicationsVEGFR-1 overexpression identifies a small subgroup of aggres...

VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy

Standard

VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy. / Tsourlakis, Maria Christina; Khosrawi, Puya; Weigand, Philipp; Kluth, Martina; Hube-Magg, Claudia; Minner, Sarah; Koop, Christina; Graefen, Markus; Heinzer, Hans; Wittmer, Corinna; Sauter, Guido; Krech, Till; Wilczak, Waldemar; Huland, Hartwig; Simon, Ronald; Schlomm, Thorsten; Steurer, Stefan.

In: INT J MOL SCI, Vol. 16, No. 4, 2015, p. 8591-606.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Tsourlakis, MC, Khosrawi, P, Weigand, P, Kluth, M, Hube-Magg, C, Minner, S, Koop, C, Graefen, M, Heinzer, H, Wittmer, C, Sauter, G, Krech, T, Wilczak, W, Huland, H, Simon, R, Schlomm, T & Steurer, S 2015, 'VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy', INT J MOL SCI, vol. 16, no. 4, pp. 8591-606. https://doi.org/10.3390/ijms16048591

APA

Tsourlakis, M. C., Khosrawi, P., Weigand, P., Kluth, M., Hube-Magg, C., Minner, S., Koop, C., Graefen, M., Heinzer, H., Wittmer, C., Sauter, G., Krech, T., Wilczak, W., Huland, H., Simon, R., Schlomm, T., & Steurer, S. (2015). VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy. INT J MOL SCI, 16(4), 8591-606. https://doi.org/10.3390/ijms16048591

Vancouver

Tsourlakis MC, Khosrawi P, Weigand P, Kluth M, Hube-Magg C, Minner S et al. VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy. INT J MOL SCI. 2015;16(4):8591-606. https://doi.org/10.3390/ijms16048591

Bibtex

@article{e6cc8991c17b4fc28317641e3144e2b1,
title = "VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy",
abstract = "The VEGFR-1 is suggested to promote tumor progression. In the current study we analyzed prevalence and prognostic impact of the VEGFR-1 by immunohistochemistry on a tissue microarray containing more than 3000 prostate cancer specimens. Results were compared to tumor phenotype, ETS-related gene (ERG) status, and biochemical recurrence. Membranous VEGFR-1 expression was detectable in 32.6% of 2669 interpretable cancers and considered strong in 1.7%, moderate in 6.7% and weak in 24.2% of cases. Strong VEGFR-1 expression was associated with TMPRSS2:ERG fusion status as determined by fluorescence in situ hybridization (FISH) and immunohistochemistry (p < 0.0001 each). Elevated VEGFR-1 expression was linked to high Gleason grade and advanced pT stage in TMPRSS2:ERG negative cancers (p = 0.0008 and p = 0.001), while these associations were absent in TMPRSS2:ERG positive cancers. VEGFR-1 expression was also linked to phosphatase and tensin homolog (PTEN) deletions. A comparison with prostate specific antigen (PSA) recurrence revealed that the 1.7% of prostate cancers with the highest VEGFR-1 levels had a strikingly unfavorable prognosis. This could be seen in all cancers, in the subsets of TMPRSS2:ERG positive or negative, PTEN deleted or undeleted carcinomas (p < 0.0001 each). High level VEGFR-1 expression is infrequent in prostate cancer, but identifies a subgroup of aggressive cancers, which may be candidates for anti-VEGFR-1 targeted therapy.",
author = "Tsourlakis, {Maria Christina} and Puya Khosrawi and Philipp Weigand and Martina Kluth and Claudia Hube-Magg and Sarah Minner and Christina Koop and Markus Graefen and Hans Heinzer and Corinna Wittmer and Guido Sauter and Till Krech and Waldemar Wilczak and Hartwig Huland and Ronald Simon and Thorsten Schlomm and Stefan Steurer",
year = "2015",
doi = "10.3390/ijms16048591",
language = "English",
volume = "16",
pages = "8591--606",
journal = "INT J MOL SCI",
issn = "1661-6596",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "4",

}

RIS

TY - JOUR

T1 - VEGFR-1 overexpression identifies a small subgroup of aggressive prostate cancers in patients treated by prostatectomy

AU - Tsourlakis, Maria Christina

AU - Khosrawi, Puya

AU - Weigand, Philipp

AU - Kluth, Martina

AU - Hube-Magg, Claudia

AU - Minner, Sarah

AU - Koop, Christina

AU - Graefen, Markus

AU - Heinzer, Hans

AU - Wittmer, Corinna

AU - Sauter, Guido

AU - Krech, Till

AU - Wilczak, Waldemar

AU - Huland, Hartwig

AU - Simon, Ronald

AU - Schlomm, Thorsten

AU - Steurer, Stefan

PY - 2015

Y1 - 2015

N2 - The VEGFR-1 is suggested to promote tumor progression. In the current study we analyzed prevalence and prognostic impact of the VEGFR-1 by immunohistochemistry on a tissue microarray containing more than 3000 prostate cancer specimens. Results were compared to tumor phenotype, ETS-related gene (ERG) status, and biochemical recurrence. Membranous VEGFR-1 expression was detectable in 32.6% of 2669 interpretable cancers and considered strong in 1.7%, moderate in 6.7% and weak in 24.2% of cases. Strong VEGFR-1 expression was associated with TMPRSS2:ERG fusion status as determined by fluorescence in situ hybridization (FISH) and immunohistochemistry (p < 0.0001 each). Elevated VEGFR-1 expression was linked to high Gleason grade and advanced pT stage in TMPRSS2:ERG negative cancers (p = 0.0008 and p = 0.001), while these associations were absent in TMPRSS2:ERG positive cancers. VEGFR-1 expression was also linked to phosphatase and tensin homolog (PTEN) deletions. A comparison with prostate specific antigen (PSA) recurrence revealed that the 1.7% of prostate cancers with the highest VEGFR-1 levels had a strikingly unfavorable prognosis. This could be seen in all cancers, in the subsets of TMPRSS2:ERG positive or negative, PTEN deleted or undeleted carcinomas (p < 0.0001 each). High level VEGFR-1 expression is infrequent in prostate cancer, but identifies a subgroup of aggressive cancers, which may be candidates for anti-VEGFR-1 targeted therapy.

AB - The VEGFR-1 is suggested to promote tumor progression. In the current study we analyzed prevalence and prognostic impact of the VEGFR-1 by immunohistochemistry on a tissue microarray containing more than 3000 prostate cancer specimens. Results were compared to tumor phenotype, ETS-related gene (ERG) status, and biochemical recurrence. Membranous VEGFR-1 expression was detectable in 32.6% of 2669 interpretable cancers and considered strong in 1.7%, moderate in 6.7% and weak in 24.2% of cases. Strong VEGFR-1 expression was associated with TMPRSS2:ERG fusion status as determined by fluorescence in situ hybridization (FISH) and immunohistochemistry (p < 0.0001 each). Elevated VEGFR-1 expression was linked to high Gleason grade and advanced pT stage in TMPRSS2:ERG negative cancers (p = 0.0008 and p = 0.001), while these associations were absent in TMPRSS2:ERG positive cancers. VEGFR-1 expression was also linked to phosphatase and tensin homolog (PTEN) deletions. A comparison with prostate specific antigen (PSA) recurrence revealed that the 1.7% of prostate cancers with the highest VEGFR-1 levels had a strikingly unfavorable prognosis. This could be seen in all cancers, in the subsets of TMPRSS2:ERG positive or negative, PTEN deleted or undeleted carcinomas (p < 0.0001 each). High level VEGFR-1 expression is infrequent in prostate cancer, but identifies a subgroup of aggressive cancers, which may be candidates for anti-VEGFR-1 targeted therapy.

U2 - 10.3390/ijms16048591

DO - 10.3390/ijms16048591

M3 - SCORING: Journal article

C2 - 25894226

VL - 16

SP - 8591

EP - 8606

JO - INT J MOL SCI

JF - INT J MOL SCI

SN - 1661-6596

IS - 4

ER -